Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVORA 0.15/30-21 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Levonorgestrel: hepatically metabolized via CYP3A4, CYP2C19, and CYP2C9; undergoes conjugation. Ethinyl estradiol: metabolized via CYP3A4 and sulfation (SULT1E1).
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Levonorgestrel: 97-98% (SHBG, albumin); Ethinyl estradiol: 97-98% (albumin, SHBG)
~99% bound to serum albumin and sex hormone-binding globulin.
Levonorgestrel: 1.4 L/kg; Ethinyl estradiol: 2.4 L/kg; extensive tissue distribution
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: levonorgestrel ~100%; ethinyl estradiol 38-48% (first-pass metabolism)
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use caution.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute liver disease or severe (Child-Pugh C) hepatic impairment. For Child-Pugh A or B, use is not recommended; alternative contraception advised.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 21 days, then 7 days off.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. No specific geriatric dosing considerations due to lack of indication.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and smoking intensity (especially >35 years). Women >35 years who smoke should not use combination oral contraceptives.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (DVT, PE, stroke, MI),Cerebral hemorrhage,Hepatic neoplasia (benign/malignant),Gallbladder disease,Hypertension,Carbohydrate/lipid metabolism effects,Ocular lesions (e.g., retinal thrombosis),Headache/migraine,Uterine bleeding irregularities,Depression,Contact lens intolerance
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Pregnancy (known or suspected),Heavy smoking (>15 cigarettes/day) in women ≥35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food restrictions. Grapefruit juice may increase estrogen levels; avoid large quantities. Maintain consistent dietary habits to avoid interference with absorption.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: No increased risk of birth defects based on large epidemiological studies. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and hepatic adenoma. Overall, pregnancy is a contraindication for levonorgestrel/ethinyl estradiol.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Levonorgestrel and ethinyl estradiol are excreted in breast milk. M/P ratio for levonorgestrel is approximately 1.0; for ethinyl estradiol, it is 0.4. Use may reduce milk production and composition. Not recommended during lactation.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustments are applicable as use is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) would require dose modification if use were considered, but no established guidelines exist.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Levonorgestrel/ethinyl estradiol is a combination oral contraceptive. Advise patients to take at the same time daily. Breakthrough bleeding is more common in first few cycles. Missed pill management: if less than 12 hours, take immediately; if more than 12 hours, check package insert. Consider drug interactions with rifampin, certain anticonvulsants, and antibiotics. Not recommended in smokers over 35 and those with history of migraines with aura, hypertension, or thromboembolism.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill at the same time every day.,If you miss a pill, refer to the patient leaflet for instructions.,Use backup contraception (e.g., condoms) if you miss pills or have vomiting/diarrhea.,Common side effects include nausea, spotting, and breast tenderness; these often improve after 3 months.,Do not smoke while taking this medication, especially if over age 35.,This medication does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVORA 0.15/30-21 vs AFIRMELLE, answered by our medical review team.
LEVORA 0.15/30-21 is a Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVORA 0.15/30-21 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVORA 0.15/30-21 is: One tablet orally once daily for 21 days, followed by 7 tablet-free days.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVORA 0.15/30-21 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVORA 0.15/30-21 is classified as Category C. First trimester: No increased risk of birth defects based on large epidemiological studies. Second and third trimesters: Avoid use due to potential adverse effects on fetal develop. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.